Hypera's Second-Month Miracle: Semavy Is Already the Top Seller

The Brazilian pharma's GLP-1 launch moved from option to execution in Q3 — and it changes the growth algorithm.

HYPE3.SA · Earnings Call · 2026-10-28

The second month is the tell

Hypera's third quarter was not a clean growth quarter. Revenue rose 9.4% to BRL 2.4 billion and EBITDA reached BRL 782 million at a 32% margin, but the underlying mix was messy: sell-out grew 6.6% against a target market up 5.4%, while the acute respiratory category did the opposite. Management pinned the drag on a 15% decline in flu medication sales after reported flu cases fell 23% in Q3 2026, largely an El Niño effect. That is real, but it is also the kind of noise that can hide a strategic inflection. The inflection is Semavy, Hypera's semaglutide-based injectable. In its first month on the market, Semavy sold about 93,000 units and captured more than 11% of the injectable semaglutide market, reaching more than 18,000 pharmacies. By October — only the second month — it was already the company's top-selling product in sell-out. That is not a normal launch cadence for a Brazilian pharma company, and it is the reason this quarter matters.

In October, growth remains very strong and exceeds our expectations. It already positions Semavy as the company's top-selling product in sell-out. And we're still only in the product's second month of sales.
Breno Oliveira, CEO · 2026-10-28

The GLP-1 theme itself is not new for Hypera. It was the top-ranked company keyword in the second quarter of 2026, and management was already talking about the patent cliff and the size of the opportunity a year ago. “The GLP-1 line, as you know, has been growing significantly, and we believe that this will continue to happen in the future as new brands come into this market and as prices reduce.” — Breno Oliveira, CEO · 2026-08-07 What is new is execution. The company is no longer describing an option; it is reporting a product that is changing the revenue mix.

Price, supply, and the generic wave

The economics of Semavy are the key debate. Hypera launched at a 60% discount to the reference semaglutide price, yet the market expanded faster than the price fell. Breno Oliveira noted that the injectable semaglutide market roughly doubled in units between the first generic entrant in June and September, and October was bigger again. The price reduction has been a market-expansion event, not just a margin give-away. “we saw a 60% reduction versus the reference medication price. But the market grew significantly in units.” — Breno Oliveira, CEO · 2026-10-28 Management expects new competitors to enter without triggering another round of price cuts, and says Hypera has room to respond if they do. That is a confident claim, but it is supported by the supply arrangement: Hypera owns the brand, Sun Pharma manufactures, and Ramon Sanches said there are no capacity limits, only a negotiated lead time and the challenge of forecasting demand. The bigger constraint may be physician adoption. Hypera has reached about 30,000 prescribing physicians, mostly endocrinologists and cardiologists, and sees room in general practice, gynecology, and psychiatry. The company also has a portfolio for the side effects of GLP-1 use — constipation, nausea — which gives it a basket to sell alongside Semavy. Globally, the obesity/GLP-1 demand signal is still strong. The global tape shows patient with obesity among the 90-day and 30-day advancers, a reminder that the constraint is access and price, not underlying demand. Hypera's angle is not innovation; it is distribution, brand, and the Brazilian generic/similar wave. That is a different, and arguably more defensible, way to play the theme. A year ago, management sized the prize plainly: “the most recent figures are around BRL 10 billion per year. So semaglutide is about half of that.” — Breno Pires de Oliveira, CEO · 2025-10-29

The cash machine and the capital-allocation gate

The quarter also showed why the balance sheet matters. EBITDA converted 97.5% into operating cash flow, net debt fell by roughly BRL 300 million to BRL 5.6 billion — about 2x trailing EBITDA — and net income rose 16% because interest expense fell 42%. The company completed its 22nd debenture issue at CDI+0.72% and retired more expensive paper, bringing the weighted average cost of debt to CDI-0.5%. “Net income grew by 16%, driven by a 42% decrease in interest expenses.” — Ramon Sanches, CFO and IRO · 2026-10-28 Working capital continues to improve. Inventory ended at 186 days, down from 194 in the second quarter, and working capital fell to 27% of annualized revenue. Semavy should help that metric over time because it is imported as a finished product and turns faster than Hypera's typical inventory. The inventory level is no longer the emergency it was two years ago; it is now a source of cash. The capital-allocation gate is explicit: get to 1.5x net debt/EBITDA before considering buybacks or higher payouts. Management thinks that is achievable by the end of 2027, helped by lower CapEx as major projects — the oncology plant, R&D infrastructure, the Takeda product internalization — wind down. That is consistent with prior calls, but the timing has firmed. A year ago, Ramon Sanches was saying the significant CapEx reduction would come later: “we will see a significant reduction in our CapEx after 2027, maybe in 2028.” — Ramon Sanches, CFO and Investor Relations Officer · 2026-08-07 Now he is describing the investment cycle as concluding this year and early next year. “Our goal before we think about payouts to shareholders or investing in our business is to get to 1.5x net debt to EBITDA.” — Ramon Sanches, CFO and IRO · 2026-10-28

What changed, and what did not

The quarter's biggest negative revision was not in the core business. It was the institutional market, where Hypera had targeted BRL 1.5 billion in sales by 2028. Management now says that target may slip to 2030 because Anvisa approval timelines have stretched. The institutional business has grown from under BRL 100 million to around BRL 500 million, so the direction is right, but the timeline is not. “reaching BRL 1.5 billion in sales by 2028, that's our target, but maybe for the future, maybe for 2030.” — Breno Oliveira, CEO · 2026-10-28 The flu drag should also fade. Management expects some impact in Q4 and Q1, but the category is less important in those quarters, and the comparison weakens by Q3 2027. The tax reform transition — PIS/Cofins moving from 12.5% to 9% — is being managed through portfolio price rebalancing, not reimbursement, and management does not expect a material inventory effect. What has genuinely changed is the narrative. For several quarters, Hypera's story was working capital optimization, deleveraging, and defending the base. Those keywords dominated the calls. Now the lead theme is growth: GLP-1, Semavy, new launches, and a return to double-digit revenue growth in October. The old cash generation story is still there, but it has become the funding mechanism for the next phase rather than the headline. The risk is that Semavy's contribution margin is thin at launch. Marketing spend rose 13.1% in Q3, faster than sell-out, because Hypera is investing in media and medical sales teams. Management says the product is already contribution-positive — unusual for a launch — but the margin will converge toward the company average only as volumes scale. If competition surprises on price, or Anvisa delays the 2027 pipeline, the growth algorithm looks less certain. Still, the proof point is hard to dismiss. A product that becomes the top seller in its second month is a genuine company-specific event, not sector boilerplate. Hypera has spent a year telling investors the GLP-1 wave was coming; this quarter it showed the wave arriving. The next two quarters will determine whether Semavy is a one-off launch spike or the beginning of a different company.